Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43936   clinical trials with a EudraCT protocol, of which   7310   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-001142-15
    Sponsor's Protocol Code Number:NN7088-3859
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-01-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2011-001142-15
    A.3Full title of the trial
    A Multi-national Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0129-0000-1003 (N8-GP) when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A
    Ensayo multinacional para evaluar la seguridad y la eficacia, junto con la farmacocinética, de NNC 0129?0000-1003 (N8-GP) administrado para el tratamiento y la profilaxis de las hemorragias en pacientes con hemofilia A
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Multi-national Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0129-0000-1003 when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A
    Ensayo multinacional para evaluar la seguridad y la eficacia, junto con la farmacocinética, de NNC 0129?0000-1003 administrado para el tratamiento y la profilaxis de las hemorragias en pacientes con hemofilia A
    A.3.2Name or abbreviated title of the trial where available
    pathfinder? 2
    A.4.1Sponsor's protocol code numberNN7088-3859
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1119-7416
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovo Nordisk A/S
    B.1.3.4CountryDenmark
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovo Nordisk A/S
    B.4.2CountryDenmark
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovo Nordisk A/S
    B.5.2Functional name of contact pointGlobal Clinical Registry (GCR,1452)
    B.5.3 Address:
    B.5.3.1Street AddressVandtaarnsvej 114, VTB
    B.5.3.2Town/ citySoeborg
    B.5.3.3Post codeDK-2860
    B.5.3.4CountryDenmark
    B.5.6E-mailclinicaltrials@novonordisk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameN8-GP rFVIII
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 1309086-46-1
    D.3.9.2Current sponsor codeNNC129-1003
    D.3.10 Strength
    D.3.10.1Concentration unit U unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Haemophilia A
    Hemofilia A
    E.1.1.1Medical condition in easily understood language
    Bleeding disorder type A
    Trastorno hemorrágico: Deficiencia del Factor VIII.
    E.1.1.2Therapeutic area Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10018937
    E.1.2Term Haemophilia A
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - To evaluate the immunogenicity of NNC 0129-0000-1003 (hereafter referred to as N8-GP) in previously treated patients with Haemophilia A
    - To evaluate the clinical efficacy of N8-GP in bleeding prophylaxis (number of bleeds during prophylaxis)
    - Evaluar la inmunogenicidad del NNC 0129-0000-1003 (en adelante N8-GP) en los pacientes con hemofilia A y tratamiento previo.
    -Evaluar la eficacia clínica del N8-GP para la profilaxis de la hemorragia (número de episodios hemorrágicos durante la profilaxis).
    E.2.2Secondary objectives of the trial
    - To evaluate the clinical efficacy of N8-GP when treating bleeds in patients with haemophilia A
    - To evaluate the safety of N8-GP when used for prevention of bleeds and treatment of bleeds in patients with haemophilia A
    - To evaluate PK properties of N8-GP
    - To evaluate Patient Reported Outcomes
    - To evaluate the health economic impact of N8-GP treatment
    - Generation of a population based PK-model for N8-GP
    - Evaluar la eficacia clínica del N8-GP para el tratamiento de las hemorragias en los pacientes con hemofilia A.
    -Evaluar la seguridad del N8-GP cuando se utiliza para la prevención de las hemorragias y el tratamiento de hemorragias en los pacientes con hemofilia A.
    -Evaluar las propiedades farmacocinéticas del N8-GP.
    -Evaluar los resultados comunicados por los pacientes.
    -Evaluar el efecto del tratamiento con N8-GP sobre la economía sanitaria.
    -Elaborar un modelo farmacocinético poblacional del N8-GP.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Male patients with severe congenital haemophilia A (FVIII activity <1%, according to medical records)
    - Documented history of at least 150 EDs to other FVIII products
    - Age ? 12 years and body weight ? 35 kg (except for Croatia and The Netherlands where the lower age limit will be 18 years)
    -Varones con hemofilia A congénita grave (actividad del FVIII < 1% según la historia clínica).
    -Antecedentes documentados de al menos 150 DE a cualquier otro producto de FVIII.
    -Edad ? 12 años y peso corporal ?35 kg (salvo en Croacia y Países Bajos, donde el límite inferior de edad será de 18 años).
    E.4Principal exclusion criteria
    - Previous participation in this trial defined as withdrawal after administration N8-GP
    - Any history of FVIII inhibitors
    - FVIII inhibitors ? 0.6 BU/mL at screening
    - HIV positive, defined by medical records with CD4+ count ?200/µL or a viral load of >400000 copies/mL If the data is not available in medical records within last 6 months, CD4+ will be measured at the screening visit
    - Congenital or acquired coagulation disorders other than haemophilia A
    - Previous significant thromboembolic events (e.g. myocardial infarction, cerebrovascular disease or deep venous thrombosis) as defined by available medical records
    - Platelet count < 50,000 platelets/µL (laboratory value at the screening visit)
    - ALAT > 3 times the upper limit of normal reference ranges at central laboratory
    - Creatinine level ? 1.5 times above upper normal limit (according to central laboratory reference ranges)
    - Ongoing immune modulating or chemotherapeutic medication
    - Participación previa en este ensayo, definida como la retirada tras la administración de N8-GP.
    - Antecedentes de inhibidores del FVIII
    - Título de inhibidores del FVIII ? 0,6 UB/ml en el momento de la selección.
    - Infección por el VIH, definida por un recuento de linfocitos CD4+ ? 200/ µl o una carga viral > 400.000 copias/ml recogidos en la historia clínica. En caso de que la historia clínica no contenga estos datos correspondientes a los últimos 6 meses, se medirá el recuento de linfocitos CD4+ en la visita de selección.
    - Trastornos de la coagulación congénitos o adquiridos distintos de la hemofilia A.
    - Antecedentes de episodios tromboembólicos de importancia clínica (por ejemplo, infarto de miocardio, enfermedad cerebrovascular o trombosis venosa profunda) recogidos en la historia clínica.
    - Recuento de plaquetas < 50.000 /µl (valor analítico en la visita de selección).
    - ALAT > 3 veces el límite superior del intervalo de referencia de la normalidad del laboratorio central.
    - Valor de creatinina ? 1,5 veces el límite superior de la normalidad (según los intervalos de referencia del laboratorio central).
    - Tratamiento en curso con inmunomoduladores o quimioterápicos.
    E.5 End points
    E.5.1Primary end point(s)
    - The Incidence rate of FVIII-inhibitors ?0.6 BU
    - Annualised bleeding rate in the prophylaxis arm
    - Incidencia de un título de inhibidores del FVIII ? 0,6 UB.
    - Tasa anualizada de hemorragias en el grupo de profilaxis.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The endpoints will be analysed based on all available information until the end of trial (EOT) visit and up to approximately 19 months.
    Las variables se analizarán basándose en toda la información disponible hasta el final del ensayo (FE), es decir, hasta aproximadamente 19 meses.
    E.5.2Secondary end point(s)
    - Haemostatic effect of N8-GP when used for treatment of bleeds, assessed on a four-point scale for haemostatic response (excellent, good, moderate and none) by counting excellent and good as success and moderate and none as failure.
    - Efecto hemostático del N8-GP cuando se utiliza para el tratamiento de las hemorragias, evaluado en una escala de cuatro puntos según la respuesta hemostática (excelente, buena, moderada o nula) y contando como éxitos las respuestas excelentes y buenas y como fracasos las respuestas moderadas o nulas
    E.5.2.1Timepoint(s) of evaluation of this end point
    The endpoints will be analysed based on all available information until the end of trial (EOT) visit and up to approximately 19 months.
    Las variables se analizarán basándose en toda la información disponible hasta el final del ensayo (FE), es decir, hasta aproximadamente 19 meses.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA30
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Croatia
    Denmark
    France
    Germany
    Hungary
    Italy
    Japan
    Korea, Republic of
    Malaysia
    Netherlands
    Norway
    Russian Federation
    Spain
    Sweden
    Switzerland
    Taiwan
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 15
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 15
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 117
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 65
    F.4.2.2In the whole clinical trial 132
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    N/A
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-01-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2011-12-28
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-12-10
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA